Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...
Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback